Skip to main content

Table 2 Patient demographic and clinical characteristics

From: A retrospective analysis of health care utilization for patients with mitochondrial disease in the United States: 2008–2015

Characteristics MD Pediatric MD Adult
Population, n (%) 3790 (46.3) 4390 (53.7)
Agea in years, mean 7.4 42.3
Gendera, n
 Female (n = 4348) (%) 1605 (36.9) 2743 (63.1)
 Male (n = 3832) (%) 2185 (57.0) 1647 (43.0)
Comorbidities, >  10% (%)
  Seizure disorders and convulsions (47.4) Diabetes (33.3)
Asthma (30.2) Asthma (22.6)
Autistic disorder (25.4) Seizure disorders and convulsions (22.5)
Amyloidosis, porphyria, and other metabolic disorders (24.3) Major depressive and bipolar disorders (18.3)
Cerebral palsy, except quadriplegic (19.1) Congestive heart failure (17.2)
Down syndrome, Fragile X, other chromosomal anomalies, and congenital malformation syndromes (16.8) Adrenal, pituitary, and other significant endocrine disorders (15.4)
Disorders of the immune mechanism (16.4) Specified heart arrhythmias (13.6)
Spina Bifida, and other brain/spinal, nervous system congenital anomalies (16.3) Acute pancreatitis/other pancreatic disorders and intestinal malabsorption (12.8)
Cardio-respiratory failure and shock, including respiratory distress syndromes (15.3) Amyloidosis, porphyria, and other metabolic disorders (11.8)
Pervasive developmental disorders, except autistic disorder (12.5) Cardio-respiratory failure and shock, including respiratory distress syndromes (10.4)
Congestive heart failure (11.9) Chronic obstructive pulmonary disease, including bronchiectasis (10.4)
Parkinson’s, Huntington’s, and Spinocerebellar disease, and other neurodegenerative disorders (11.5)
Acute pancreatitis/other pancreatic disorders and intestinal malabsorption (11.3)
Atrial and ventricular septal defects, patent ductus arteriosus, and other congenital heart/circulatory disorders (10.2)
Myasthenia Gravis/myoneural disorders and Guillain-Barre syndrome/Inflammatory and toxic neuropathy (9.8)
Congenital/Developmental Skeletal and Connective Tissue Disorders (9.5)
  1. a3 patients did not have age or gender data available